Weight and metabolic health
Insulin resistance
Insulin resistance means the body needs more insulin to control glucose. It commonly accompanies excess visceral fat, but context and actual glucose measures matter.
Potential benefits explored
Improved glucose handling.
Semaglutide and tirzepatide have human metabolic evidence; MOTS-c represents a more experimental metabolic-signalling direction.
Practical interpretation
Assess glucose/HbA1c, adiposity, activity, sleep and medicines; use weight and diabetes care where indicated.
Meaningful outcomes: Appropriate glucose measures and metabolic health outcomes.
Compare the compounds studied for Insulin resistance
Members see the full evidence picture for this condition: every compound studied, graded per condition from strong human evidence through to preclinical-only and negative findings, with human and animal results, risks, combination evidence and cited sources — plus how each compound maps to the research materials we list, with live pricing and stock.
Research reference for laboratory materials only. Not medical advice and not a recommendation for human use. Research cut-off: 30 September 2026.